{"id":"NCT04575597","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)","officialTitle":"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-10-19","primaryCompletion":"2022-05-05","completion":"2022-05-05","firstPosted":"2020-10-05","resultsPosted":"2023-06-28","lastUpdate":"2023-06-28"},"enrollment":1735,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Coronavirus Disease (COVID-19)"],"interventions":[{"type":"DRUG","name":"Molnupiravir","otherNames":["MK-4482"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Part 1: Molnupiravir 200 mg","type":"EXPERIMENTAL"},{"label":"Part 1: Molnupiravir 400 mg","type":"EXPERIMENTAL"},{"label":"Part 1: Molnupiravir 800 mg","type":"EXPERIMENTAL"},{"label":"Part 1: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part 2: Molnupiravir 800 mg","type":"EXPERIMENTAL"},{"label":"Part 2: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29","primaryOutcome":{"measure":"Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis)","timeFrame":"Up to 29 days","effectByArm":[{"arm":"Part 1: Molnupiravir 200 mg","deltaMin":1.4,"sd":null},{"arm":"Part 1: Molnupiravir 400 mg","deltaMin":3.9,"sd":null},{"arm":"Part 1: Molnupiravir 800 mg","deltaMin":4.1,"sd":null},{"arm":"Part 1: Placebo","deltaMin":5.4,"sd":null},{"arm":"Part 2: Molnupiravir 800 mg","deltaMin":7.3,"sd":null},{"arm":"Part 2: Placebo","deltaMin":14.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG004 vs OG005","p":"0.0012"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":173,"countries":["United States","Argentina","Brazil","Canada","Chile","Colombia","Egypt","France","Germany","Guatemala","Israel","Italy","Japan","Mexico","Philippines","Poland","Russia","South Africa","Spain","Sweden","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["38319179","40025641","37995070","37466374","37017631","36648627","35667065","34914868"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":74},"commonTop":["COVID-19","Diarrhoea"]}}